Influence of Heparin and a Low Molecular Weight Heparinoid on Specific Endogenous and Exogenous Fibrinolytic Factors during Rest and Exercise

Abstract

SummaryThe effects of heparin (5,000 IU i.v.) and the low molecular weight heparinoid Org 10172 (Orgaran®) (3,250 anti-Xa units i. v.) on components of the fibrinolytic system were studied in two double-blind, randomised, placebo-controlled, cross-over trials using healthy subjects. In study A (n = 6) the effects were studied during rest and standardized exercise and in study B (n = 6) during a low dose infusion of recombinant tissue-type plasminogen activator (rt-PA; 80 µg over 16 min). At rest, heparin and Org 10172 did not influence the plasma concentrations of endogenous t-PA antigen, and activity, urokinase-type PA (u-PA) antigen, plasmin activatable pro-urokinase (scu-PA), active urokinase (tcu-PA) and plasminogen activator inhibitor-1 (PAI-1) antigen. Recombinant t-PA antigen and activity during rt-PA infusion were also not affected. During exercise, neither heparin nor Org 10172 influenced the area under the curve (AUC) of t-PA and u-PA antigen and t-PA activity when compared with placebo. Unexpectedly, after heparin the AUC of t-PA activity was 49% larger (range +19 to +245%) than after Org 10172 (p <0.05). The last difference was considered spurious. scu-PA, tcu-PA and PAI-1 antigen levels at 2 min after termination of exercise were unaffected by both compounds (p >0.05). Sulphated polysaccharides do not increase fibrinolytic activity of the plasma by changing the concentrations of the components of the fibrinolytic system.

Efficacy of Thrombolytic (rt-PA) Therapy in Old Stroke Patients: The Perugia Stroke Unit Experience

“…Liver blood How is a major determinant of the rate of clearance of alteplase; elderly patients receiving alteplase therefore might be exposed to higher blood concentrations over time (21). Another reason might be the shorter lifetime of the oldest leading to a more "conservative approch."…”

Quantification of heparin‐induced TFPI release: a maximum release at low heparin dose

“…The main source of circulating t‐PA is the endothelium where t‐PA is stored in intracellular bodies [10]. Despite numerous studies on the effects of heparin on fibrinolysis, controversy exists on the effects of heparin on t‐PA concentrations [9, 11, 12].…”

Local tissue factor pathway inhibitor release in the human forearm

“…We here report that, despite substantial increases in blood flow and t-PA release, we were unable to detect increases in plasma TFPI concentrations using either endothelium-dependent or -independent vasodilators. Given that heparin also does not release t-PA (31), it would appear that the pathways of t-PA and TFPI release are mediated through distinct cellular mechanisms. This is not entirely unexpected given that previous work has shown release of other endothelium-derived factors, such as von Willebrand factor, are also not induced by substance P (24) or bradykinin (27).…”